<DOC>
	<DOCNO>NCT02330991</DOCNO>
	<brief_summary>The purpose study evaluate clinical benefit safety two different Dose-Intense temozolomide regimens（one-week on/one-week regimen versus continuous dose-intense regimen）in patient glioblastoma first relapse .</brief_summary>
	<brief_title>A Trial One-week on/One-week Off Temozolomide Versus Continuous Dose-Intense Temozolomide Patients With Glioblastoma Multiforme First Relapse</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Participants must histopathologicallyconfirmed , supratentorial , glioblastoma . 2 . Participants must receive firstline treatment regimen consist RT plus concomitant temozolomide follow adjuvant temozolomide . 3 . Participants must first recurrence progression glioblastoma firstline treatment regimen . 4 . Participants must demonstration recurrent disease MRI follow prior therapy . 5 . Participants must bidimensionally measurable disease minimum measurement 1 cm one dimension MRI perform within 14 day prior first treatment . If receiving corticosteroid , participant must stable decrease dose corticosteroid least 5 day prior baseline MRI . 6 . Participants must develop progressive disease receive prior therapy must interval least 12 week completion radiation concomitant temozolomide therapy study entry ( unless progressive tumor growth outside radiation field histopathological confirmation recurrent tumor ) 7 . Age 1875 year old . 8 . Life expectancy least 12 week . 9 . Karnofsky performance status least 60 10 . Participants must able adhere dose visit schedule , agree record medication time , concomitant medication , adverse event ( AEs ) accurately consistently daily diary . 11 . 20 paraffinsections glioblastoma tissue must available . 12 . Participants must normal organ marrow function define : leukocyte &gt; 4.0×10^9/L，platelets &gt; 100×10^9/L，Hemoglobin &gt; 10 g/dl，Serum creatinine &lt; 1.5fold upper normal range，AST ALT &lt; 2fold upper normal range , Alkaline phosphatase &lt; 3fold upper normal range . 13 . Female male subject childbearing potential must agree use medically accept method adequate contraception . 1 . Treatment chemotherapy temozolomide prior enrollment . 2 . Progressive recurrent glioblastoma document MRI earlier 12 week completion radiotherapy . 3 . History cancer . 4 . HIV infection . 5 . Women pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>glioblastoma</keyword>
	<keyword>relapse</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>glioblastoma first relapse</keyword>
</DOC>